RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

This study has been terminated.
(Business Decision, no patients were enrolled in the study)
Sponsor:
Information provided by (Responsible Party):
Reata Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00538343
First received: September 28, 2007
Last updated: June 4, 2012
Last verified: June 2012
  Purpose

The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.


Condition Intervention Phase
Brain Metastases
Drug: berubicin hydrochloride (RTA 744)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Efficacy and Tolerability Study of RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Resource links provided by NLM:


Further study details as provided by Reata Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • To evaluate the efficacy of RTA 744 in reducing intracranial tumor on contrast-enhanced MRI of breast cancer patients with progression of brain metastases following whole brain radiotherapy (WBRT). [ Time Frame: 21 Days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the efficacy of RTA 744 on intracranial tumor as measured by intracranial objective response rate (Intracranial ORR) determined by modified RECIST criteria and by volumetric analysis. [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • To evaluate overall objective response rate after administration of RTA 744. [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • To evaluate the efficacy of RTA 744 on intracranial tumor as measured by intracranial Time To Progression. [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • To evaluate progression free survival (PFS) after administration of RTA 744. [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • To evaluate overall survival (OS) after administration of RTA 744. [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
  • To evaluate the safety and tolerability of RTA 744 administered at 7.5 mg/m2/day for 3 consecutive days on a 21-day cycle. [ Time Frame: 18 weeks ] [ Designated as safety issue: Yes ]
  • To evaluate the impact of RTA 744 on quality of life through the FACT-B and modified FACT-Br questionnaires. [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]

Enrollment: 14
Study Start Date: October 2007
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Detailed Description:

RTA 744 is a novel, anthracycline that has shown the ability to circumvent ATP-binding cassette transporters (Multidrug Resistance Protein 1, Breast Cancer Resistance Protein, P-glycoprotein) in vitro. This action enables RTA 744 to penetrate across the blood brain barrier. In a Phase I safety study, RTA 744 was shown to be generally well tolerated in patients with recurrent glioblastoma multiforme (GBM). Additionally, anti-tumor activity was observed. Breast cancer is known to be sensitive to anthracycline therapy. Based on the preliminary Phase I clinical results and the sensitivity of breast cancer to anthracycline therapy, this Phase II study will investigate the safety and efficacy of RTA 744 in patients with breast cancer and metastatic disease to the brain which has progressed following whole brain irradiation.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically-confirmed adenocarcinoma of the breast with at least one evaluable brain lesion ( ≥ 1 cm in one dimension) on contrast-enhanced MRI after WBRT and documented intracranial failure/progression i. Presence of any new lesion(s); or ii. ≥ 25% increase in bi-dimensional measurement of existing tumor
  2. Definitive radiotherapy ≥ 3000 cGy for documented CNS disease completed ≥ 4 weeks prior to initiation of protocol therapy
  3. ≥ 2 weeks since stereotactic radiosurgery or gamma knife therapy
  4. ≥ 4 weeks since neurosurgery (open brain or stereotactic brain biopsy). Patients must have completely recovered from the side effects of surgical procedure.
  5. ≥ 2 weeks since major surgery (other than neurosurgical procedure) and complete recovery from this surgical procedure.
  6. Most recent chemotherapeutic treatment regimen completed ≥ 2 weeks prior to study entry provided toxicities have resolved.

    i. Hormone receptor positive patients must have progressed on one prior hormonal AND at least one prior chemotherapy course in the metastatic setting.

    ii. Hormone receptor negative patients must have progressed on at least one prior chemotherapy course in the metastatic setting.

    iii. Her2 positive patients must have progressed on at least one prior chemotherapeutic and one Her2-targeted combination course in the metastatic setting.

  7. Life expectancy ≥ 12 weeks.
  8. Patients receiving corticosteroids must have been on a stable dose for 2 weeks prior to study enrollment.
  9. LVEF ≥ 50% on MUGA or ECHO
  10. ECOG performance status of 0-2.
  11. Laboratory values confirmed within 14 days of initiation of study therapy: Granulocytes ≥ 1,500/μL; Lymphocytes ≥ 1,000/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥ 9 gm/dL; Total Bilirubin < 1.5 times upper limit of normal (ULN); ALT and AST < 1.5 times ULN (< 5 times ULN in patients with liver metastases); Creatinine < 1.5 times ULN
  12. Women of childbearing potential must have negative serum pregnancy test, and must agree to use adequate contraceptive method during administration of study treatment and for three months after completing treatment.
  13. Cognitive ability to provide written informed consent and comply with study requirements including follow-up procedures.

Exclusion Criteria:

  1. Evidence of new or progressive metastatic disease in the brainstem or intramedullary upper spinal cord. (Metastases in the thalamus are allowed).
  2. Evidence of diffuse leptomeningeal disease on brain MRI or by previously documented CSF cytology. (Discrete dural metastases are permitted.)
  3. Evidence of impending herniation on baseline MRI.
  4. Evidence of CNS hemorrhage on baseline MRI (within 14 days of study enrollment).
  5. Grade 3 or 4 motor, sensory, or cranial neuropathy symptoms; Grade 3 or 4 seizures, headache or nausea/vomiting.
  6. Evidence of bleeding diathesis, coagulopathy or requirement for therapeutic anticoagulation.
  7. Total lifetime, cumulative anthracycline dose > 350 mg/m2.
  8. Impaired cardiac function or other significant cardiac disease or arrhythmia of any type including: Complete left bundle branch block; Severe aortic stenosis iii. Obligate use of a cardiac pacemaker; ST depression of > 1mm in ≥ 2 leads and/or T wave inversions in ≥ 2 contiguous leads; Congenital long QT syndrome; History or presence of ventricular or atrial arrhythmia; Clinically significant bradycardia; QTc > 480 msec on EKG; Uncontrolled hypertension, history of labile hypertension or history of poor compliance with anti-hypertensive regimen; New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF); History of myocardial infarction within the past 6 months within the past 6 months
  9. Concurrent or recent (within 4 weeks prior to randomization) medication(s) that may interfere with study treatment or results, i.e., immunosuppressants other than corticosteroids, enzyme-inducing anti-epileptics and agents that prolong the QTc.
  10. Concurrent or planned hormonal, chemotherapeutic, experimental, or targeted biologic therapy.
  11. Any of the following concurrent severe or uncontrolled medical condition which could compromise participation in the study: Uncontrolled diabetes; Active or uncontrolled infection; Acute or chronic liver disease (i.e. hepatitis, cirrhosis); Patients having a contraindication to MRI imaging
  12. Pregnant
  13. Inability to comply with study and/or follow-up procedures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00538343

Locations
United States, Florida
Palm Beach Cancer Institute
West Palm Beach, Florida, United States, 33401
United States, North Carolina
Presbyterian Health Care
Charlotte, North Carolina, United States, 28204
Duke University Medical Center
Durham, North Carolina, United States, 25184
Moses Cone Regional Cancer Center
Greensboro, North Carolina, United States, 27403
Forsyth Regional Cancer Center
Winston-Salem, North Carolina, United States, 27103
United States, Texas
Texas Oncology, PA
Dallas, Texas, United States, 75246
United States, Virginia
Virginia Oncology Associates
Newport News, Virginia, United States, 23606
Sponsors and Collaborators
Reata Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Reata Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00538343     History of Changes
Other Study ID Numbers: RTA 744-C-0703
Study First Received: September 28, 2007
Last Updated: June 4, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Reata Pharmaceuticals, Inc.:
brain metastases
breast cancer

Additional relevant MeSH terms:
Brain Neoplasms
Neoplasm Metastasis
Neoplasms, Second Primary
Breast Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neoplastic Processes
Pathologic Processes
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on September 16, 2014